Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Paragraph: No discussion of costs, something we always look for and wish would be provided. As already noted, the story explained that the drug “isn’t a magic bullet. The study showed that 37 percent of women who got weekly injections of it delivered prematurely, compared to 55 percent of women who got injections of a placebo.” Good discussion of concerns and ongoing monitoring of the drug’s safety. The story explains the drug “isn’t a magic bullet. The study showed that 37 percent of women who got weekly injections of it delivered prematurely, compared to 55 percent of women who got injections of a placebo.” No disease-mongering of prematurity or its consequences. The medical director of The March of Dimes was quoted throughout. (Although they are seen as having a very pro-progesterone slant that is not held by consumer/advocacy/health policy/maternity care groups in UK, Australia, and Canada. in those countries surveys of providers uniformly get low utilization responses with the reason stated being need for more data. Similar surveys of US providers (specialty and generalists) show the vast majority use >70% (as opposed to low double digits in more evidence-driven countries) and that mission creep has started. Indications for which it is not tested see regular use in the US.) There was at least the historical perspective on “the last drug thought to prevent premature birth – a synthetic estrogen called diethylstilbesterol, or DES.” The focus of the story is FDA approval of the drug. Good historical context, explaining that “Interestingly, the drug is not new — it’s just taken a long and circuitous route to approval.” It’s clear the story didn’t rely solely on a news release. Claim: FDA Approves First Drug To Prevent Preterm Births
Given that 50% of care is covered by Medicaid and 49% by private payors, the costs for this drug are invisible to the individual. It is administered in clinic or by home health nurses and does not typically have a co-pay structure although patients will sometimes tell providers they can’t afford it. News of new drug approvals can be washed over with giddy hype. But not in this story, which offered perspective, context and restraint.

Paragraph: The story mentions that the Internet-based program is a “low-cost” option for treating insomnia; however, nothing more specific regarding cost is provided. It is presumed that the site will be proprietary; if so, what are the expected usage fees? The story states that compared to the control group, the treatment group woke up fewer times, spent fewer minutes awake, and had an improved score; however, the reader is not given any quantitative data or context to determine if these improvements are really meaningful in a person’s life. The story does not mention any possible harms that may be associated with managing insomnia via an Internet-based program. For example, might people develop worsening insomnia because of reinforcement of bad habits? A comment regarding the lack of identifiable harms would have been sufficient. The story accurately described the methodology and the participants; although this could have been further improved by providing more information about the control group, namely, that they did receive any type of treatment for insomnia. Additionally, the story effectively conveyed that this was a small study with a fairly homogenous population. This story does not directly address the prevalence of insomnia, but the overall tone does not suggest disease-mongering. This story includes comments from two independent experts, as well as a study co-author. The writer also mentions that the study was funded by a grant from the National Institute of Mental Health. This story includes information on the benefits of cognitive behavioral therapy and working with a therapist for treating insomnia and briefly mentions sleep medications. The story states that this Internet-based program “could one day” be an option for treating insomnia, which suggests that it is not yet ready for prime time. The story conveyed that this is a novel treatment modality for insomnia. The story does not appear to rely on a press release and quotes multiple sources that appear to be from interviews. Claim: Internet-based therapy shows promise for insomnia
This was a generally well written and balanced story about a small exploratory study on a possible new therapy for insomnia. The story effectively describes the methodology and patient population and includes expert commentary from independent sources. The story also appropriately cautions that larger studies with a more diverse patient population are warranted to verify the results and determine their generalizability. While the story meets many of our criteria, it would have been greatly improved by providing the reader with quantitative data and some context to help determine if the results translated to any real, meaningful benefit in peoples’ lives. For example, information on the Insomnia Severity Index, which was used to measure efficacy of the Internet-based program, would have been helpful. A brief exploration of cost, and of any potential harms (or lack of), would also have substantially strengthened the piece.

Paragraph: The company said the trial will continue unchanged as per the recommendation of a data monitoring committee. The trial was testing Bristol-Myers’ drugs Opdivo and Yervoy, against Opdivo alone, in patients with advanced melanoma. The combination failed to show a statistically significant benefit in patients whose tumors had 1% or lower levels of the PD-L1 protein being targeted, the company said. The American Cancer Society estimates that about 96,480 melanoma cases will be diagnosed in the United States this year. Bristol-Myers shares were trading at $55.99 before the bell. Claim: Bristol-Myers misses main goal of late-stage skin cancer trial.

Bristol-Myers Squibb Co said on Wednesday a late-stage trial testing a combination of its cancer drugs missed a main goal of preventing skin cancer from recurring in a certain group of patients, sending its shares down nearly 1%.